SMTL ID : 8h7x.1

Crystal structure of EGFR T790M/C797S mutant in complex with brigatinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.40 Å

Oligo State

homo-dimer

Ligands

1 x 6GY: 5-chloro-N~4~-[2-(dimethylphosphoryl)phenyl]-N~2~-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine(Non-covalent)

6GY.1: 16 residues within 4Å: Chain A: L.26, F.31, V.34, A.51, M.98, Q.99, L.100, M.101, P.102, F.103, G.104, D.108, N.150, L.152, T.162, D.163 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:L.26, A:F.31, A:V.34 Hydrogen bonds: A:M.101, A:M.101, A:G.104 Salt bridges: A:D.108

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Suzuki, M. et al., A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. NPJ Precis Oncol (2024)

Release Date

2023-10-25

Peptides

Epidermal growth factor receptor: AB

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Epidermal growth factor receptor